PYXS$1.66
$1.7126
Chart
Performance
Key Stats
AI PYXS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
SellPyxis Oncology (PYXS) exhibits significant challenges across fundamental and technical indicators. While the company operates in the promising oncology space, its current financial performance, high cash burn, and negative earnings point towards substantial risk. Long-term viability is uncertain without significant funding or clinical success.
Thematic
Pyxis Oncology operates in the high-growth oncology sector, focusing on antibody-drug conjugates (ADCs) and immuno-oncology (IO) therapies. The company's development of PYX-201, PYX-106, and PYX-107 targets significant unmet needs in treating solid tumors. Strategic partnerships with Pfizer and Biosion provide validation and potential for future development.
Fundamental
Pyxis Oncology demonstrates significant fundamental weaknesses. The company has no revenue, substantial operating losses, and negative free cash flow. Its market capitalization is low, and its reliance on cash reserves and potential future funding rounds creates considerable financial risk.
Technical
Pyxis Oncology's stock is experiencing a severe downtrend, trading significantly below its 52-week high and showing weak momentum across various timeframes. Technical indicators suggest continued downside pressure.
| Factor | Score |
|---|---|
| Oncology Market Growth | 90 |
| Pipeline Potential (ADC/IO) | 70 |
| Strategic Partnerships | 85 |
| Regulatory Landscape | 60 |
| Biotechnology Innovation | 80 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 5 |
| Growth | 20 |
| Balance Sheet Health | 25 |
| Cash Flow | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 15 |
| Momentum | 50 |
| Moving Averages | 20 |
| Trading Volume | 40 |
| Support and Resistance | 20 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Cash Position
The company has a substantial cash and cash equivalents balance of $194.73 million as of Q4 2024, providing financial flexibility for operations and development.
Positive Short-Term Performance
The stock has shown positive returns over the last 5 days (+10.62%) and 1 month (+13.64%), indicating recent investor interest and upward price momentum.
Bearish Points (8)
Significant Long-Term Decline
The stock has experienced substantial losses over the past 6 months (-20.38%), Year-to-Date (-26.04%), and 1 year (-67.36%), indicating significant negative market sentiment and value destruction.
Negative Earnings Per Share (EPS)
The trailing EPS is negative (-$1.61), and the company has consistently reported losses, making traditional valuation multiples like P/E ratio not applicable or highly negative, signaling a lack of profitability.
Calendar
August 2025
12
Next Earnings Date
H: $-0.34
A: $-0.35
L: $-0.36
Profile
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Seasonals
Price Target
6.20 USD
The 39 analysts offering 1 year price forecasts for PYXS have a max estimate of 8.00 and a min estimate of 5.00.